Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391818 · ClinicalTrials.gov registry record
The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients
A clinical trial, sponsored by OSF Healthcare System.
- Completed
- Registry status
- 19
- Enrollment target
NCT02391818 is a clinical trial that has completed, run by OSF Healthcare System. The registered enrollment target is 19 participants.
The verdict
NCT02391818 has completed, sponsored by OSF Healthcare System.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to quantify the balance impairments during and after taxane chemotherapy. Disability due to balance impairments caused by chemotherapy induced peripheral neuropathy (CIPN) can cause falls, injury, and a decline in independence. This results in poor treatment outcomes such as greater morbidity and mortality, inability to complete treatment protocols, self-limitation of activity, and diminished quality of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-06-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02391818
The ClinicalTrials.gov registry entry for NCT02391818 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSF Healthcare System, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02391818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02391818 about?
NCT02391818 is a clinical study titled "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients". The purpose of this study is to quantify the balance impairments during and after taxane chemotherapy. Disability due to balance impairments caused by chemotherapy induced peripheral neuropathy (CIPN) can cause falls, injury, and a decline in independence. This results in poor treatment outcomes suc...
What is the current status of trial NCT02391818?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2015-02. Estimated completion is 2017-06-16.
Who is sponsoring clinical trial NCT02391818?
This trial is sponsored by OSF Healthcare System, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.